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Abstract
There is substantial interindividual variability in the efficacy and tolerability of antican-
cer drugs. Such differences can be greater between individuals of different ethnicities. 
The clinical studies demonstrate that individuals from Asia (East Asia) are more sus-
ceptible to the effects of platinum-containing chemotherapies than their Western coun-
terparts. To determine whether population-related genomics (i.e., frequencies of DNA 
polymorphisms) contribute to differences in patient outcomes, polymorphisms in 109 
genes involved mainly in xenobiotic metabolism, DNA repair, the cell cycle, and apopto-
sis were tested in Russian (Caucasians) and Yakut (North Asians) ovarian cancer patients 
receiving cisplatin-based chemotherapy. Totally, 232 polymorphisms were genotyped in 
individual DNA samples using conventional PCR and arrayed primer extension technol-
ogy. Single nucleotide polymorphisms (SNPs) in more than 30 genes were found to be 
associated with one or more of clinical end points (i.e., tumor response, progression-free 
survival, overall survival, and side effects). However, all associations between SNPs and 
clinical outcomes were specific for each of ethnic group studied. These findings let us to 
propose the existence of distinctive ethnic-related characteristics in molecular mecha-
nisms determining the sensitivity of patients to platinum drug effects.
Keywords: cisplatin, DNA polymorphisms, ethnic diversity, chemotherapy, ovarian 
cancer
1. Introduction
There is substantial interindividual variability in the efficacy and tolerability of pharmaceuticals, 
including anticancer drugs. Such differences can be greater between individuals of different 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
ethnicities [1]. Currently, pharmacoethnicity, or ethnic diversity in drug effectiveness and/or 
toxicity, is an increasingly recognized factor for accounting interindividual variations in drug 
response [2]. Although the reasons underlying ethnic diversity in drug response are likely mul-
tifactorial [3], the results of numerous population studies suggest that they may be attributed, 
at least in part, to the interpopulation differences in frequencies of DNA polymorphisms – 
inherited variations at the DNA sequence level [4–6]. In terms of FST, the most commonly used 
measure of population differentiation; the proportion of such differences is 5–13% of total 
genetic diversity depending on the type of polymorphic markers chosen [6]. The opponents of 
ethnic-/race-based explorations in pharmacogenomics often consider these portions of varia-
tion as non-essential in the context of considerably larger proportions of within population 
variation which represents the average difference between members of the same population 
and accounts for 87–95% of total variance [7, 8]. Nevertheless, significant differences in the 
population prevalence of functionally impaired allelic variants of genes may create a potential 
for ethnic differences in responses to drugs that are detoxified (transported or targeted) by the 
proteins that are encoded by those genes [9–11]. A prominent example how population-based 
genetic differences can affect the drug response is the significantly greater risk for Stevens-
Johnson syndrome and toxic epidermal necrolysis among East/Southeast Asian carbamaze-
pine users, particularly Han-Chinese, Thais, and Malaysians, that has been associated with 
HLA-B*1502 allele [12]. The relationship was not evident in non-Asian patients as well as in 
Japanese and Koreans due to infrequency of the allele in these populations. Another example 
is the lower average warfarin requirements of Asians linked to the higher frequency of AA 
genotype at SNP rs9923231 upstream of VKORC1 gene among them [13]. Finally, consider-
ing potential pharmacoethnicity of anticancer drugs, one of the most illustrative examples, 
although not associated with germline variations, is the higher response rate to EGFR inhibi-
tors (e.g., gefitinib) of Asian (East Asian) lung cancer patients compared to Caucasians that 
correlates to higher frequencies of activating EGFR mutations in East Asians [14].
Keeping all that in mind, we carried out a comparative study aimed to explore the genetic 
bases of differences between Asian and Caucasian cancer patients in their sensitivity to the 
effects of platinum-containing chemotherapy. Platinum-based drugs are among the most 
widely used cytotoxic agents for the treatment of many types of cancer [15]. The first infor-
mation about lesser tolerance of Asian patients to standard, approved for Europeans, doses 
of platinum-containing regimens came from Japanese physicians [16]. In both individual 
small studies and some common arm trials conducted in Japan and by Southwest Oncology 
Group, the higher frequency of toxicity, particularly hematologic toxicity, was registered in 
Asian patients than non-Asians (mostly Caucasians) [1, 17]. Moreover, it was also found that 
the incidence of toxicity was still higher among Asians even after appropriate dose reduc-
tion [1]. Although some comparative pharmacogenetic studies have been conducted, the rea-
sons underlying the higher sensitivity/toxicity of Asians to the systemic platinum-containing 
therapy are not yet well understood [18–20]. To assess the effect of population genomics 
on difference in patient response, we comparatively explored the results of cisplatin-based 
chemotherapy in Russian (Caucasians) and Yakut (North Asians) ovarian cancer patients. 
Principal component analysis, performed by us using genotype data of a common set of 
125,000 genome-wide SNPs, demonstrated significant differences between gene pools of 
Asian and non-Asian populations (Figure 1).
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The estimates, obtained using the same set of polymorphic markers, showed that a portion 
of variation accounted for population-related differences, FST, in allele frequency between 
Russians and Yakuts was as high as 0.08, creating the potential for searching a causative 
polymorphism(s) with corresponding prevalence in population frequency. In the current 
study such candidates were searched among 232 polymorphisms from 109 genes involved 
mainly in xenobiotic metabolism, DNA repair, the cell cycle, and apoptosis.
2. Materials and methods
2.1. Patients
Ovarian cancer patients were identified and treated between 2003 and 2007 years at the N. N. 
Blokhin Cancer Research Centre and the Yakutsk Republic Cancer Clinic. Once identified, 
patients were invited to participate and were enrolled after they signed an informed consent. 
Detailed procedures of patient enrolment and data collection have been described previously 
[21, 22]. Briefly, unrelated Russian and Yakut women with morphologically confirmed epi-
thelial ovarian carcinoma, who had received no previous chemotherapy or radiation therapy, 
were recruited. The upper age limit was 65 years. Exclusion criteria were serious concomitant 
Figure 1. Genetic structure of Eurasian populations (based on 125,000 autosomal SNPs). The first two PCs are shown. 
Each individual is represented by a sign and the label corresponding to their self-identified population origin.
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diseases (diabetes, uncontrolled hypertension, myocardial infarction within the last 6 months, 
etc.), and clinically significant hearing impairment (grade 2 or higher). To ascertain ethnic-
ity, women completed a questionnaire about their ancestry; only self-described Russian and 
Yakut patients with no history of interethnic marriages in the past two generations were 
recruited. Before the initiation of chemotherapy, venous blood samples were obtained for 
genetic testing. The chemotherapy regimen was intravenous cisplatin (100 mg/m2) plus cyclo-
phosphamide (600 mg/m2) on day 1, every 3 weeks, for a maximum of 6 cycles. Intraperitoneal 
chemotherapy and radiotherapy were not allowed. Toxicity of the treatment was described 
according to standard National Cancer Institute Common Toxicity Criteria version 2.0 [23]. 
All patients were assessed for the maximal grades of nephrotoxicity, ototoxicity, neurotoxic-
ity, emesis, neutropenia, anemia, and thrombocytopenia.
The tumor response was assessed every 2 cycles. After the completion of chemotherapy, the 
patients were followed-up for disease relapse and survival. Patients with progressive disease 
were treated with second-line chemotherapy, mostly taxane based. The study protocol and 
informed consent form were approved by the Ethics Committee of the N. N. Blokhin Cancer 
Research Centre.
2.2. Genotyping
DNA was isolated from the venous blood samples (leukocytes) using a conventional approach 
including proteinase K treatment with subsequent phenol-chloroform extraction [24]. Some 
polymorphisms (Table 1) were genotyped using a polymerase chain reaction restriction frag-
ment length polymorphism (RFLP)-based technique or determined directly through evalua-
tion of their PCR product lengths.
Other polymorphisms were genotyped using a microarray “DNA repair single nucleotide 
polymorphism detection test” (version 2, Asper Biotech, Tartu, Estonia). The microarray gen-
otypes 228 SNPs in 106 genes involved in1 DNA repair, cell cycle control, apoptosis, and xeno-
biotic metabolism. Most of manually genotyped loci were also in the list of the microarray’s 
polymorphisms and served as controls of genotyping efficiency. To check into account the 
potential mistakes in genotyping with the microarray [25], all polymorphisms, which were 
associated with any clinical endpoints, were additionally tested using the RFLP method.
2.3. Statistical analysis
A permutation exact test, a two-sided Fisher exact test, and a χ2 test were used to determine 
the relationship between the variables and alleles/genotypes tested. Correlations between sur-
vival and genotype or genetic polymorphism were assessed using the Kaplan-Meier product 
limit method and the log-rank test. The significance of associations was set at P < 0.05 [26]. 
The statistical analyses were performed using the Statistica software (version 6.0, StatSoft, 
Inc., Tulsa, OK, USA) or the IBM SPSS Statistics software package (version 19, SPSS, Inc., IBM 
Company, IBM Corporation, Armonk, NY, USA), GraphPadInStat (version 3.00, GraphPad 
Software, San Diego, CA, USA), and the PowerMarker software (version 3.0) [27].
1Alternative variant – “genes which are involved in”.
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3. Results and discussion
During 2003–2007 years, 104 Russian patients and 87 Yakut patients were enrolled in the 
study. The median age of patients was 52 and 51 years, respectively. The majority of patients 
in both groups had stage III disease (72 and 53 women, respectively). Stages I, II, and IV were 
detected in 14, 6, and 10 Russian patients and 1, 8, and 25 Yakut patients. A total of 21 Russian 
patients and 11 Yakut patients were receiving adjuvant chemotherapy and were not eligible 
for evaluation of tumor response (i.e., they had no residual disease after surgery). Overall 
response rates, comprising complete and partial responders, were 85% in the Russian group 
and 58% in the Yakut group.
Polymorphism #rs ID Genotypes (No. patients)* P
GSTA1 − 69 C/T rs3957357 CC (43/60) CT (49/22) TT (12/5) 0.0007
GSTM1 gene deletion 0/0 (47/28) +/0** (57/59) NA 0.0754
GSTM3 AGG deletion rs1799735 AGG/AGG (83/75) AGG/− (16/12) −/− (5/0) 0.1054
GSTM3 Val224Ile rs7483 Val/Val (39/30) Val/Ile (57/37) Ile/Ile (8/20) <0.0001
GSTP1 Ile105Val rs1695 Ile/Ile (41/67) Ile/Val (53/17) Val/Val (10/3) <0.0001
GSTP1 Ala114Val rs1138272 Ala/Ala (80/84) Ala/Val (24/3) ―*** 0.0001
GSTT1 gene deletion 0/0 (18/22) +/0** (86/65) NA 0.2123
ERCC1 19007 T/C rs11615 TT (43/53) TC (46/29) CC (15/5) 0.0146
ERCC1 8092 C/A rs3212986 CC (61/52) CA (37/31) AA (6/4) 0.9351
ERCC2 Asp312Asn rs1799793 Asp/Asp (34/66) Asp/Asn (50/19) Asn/Asn (20/2) <0.0001
ERCC2 Lys751Gln rs13181 Lys/Lys (28/67) Lys/Gln (54/18) Gln/Gln (22/2) <0.0001
XRCC1 Arg194Trp rs1799782 Arg/Arg (94/69) Arg/Trp (10/18) ― 0.0398
XRCC1 Arg280His rs25489 Arg/Arg (95/80) Arg/His (9/6) His/His (0/1) 0.5007
XRCC1 Arg399Gln rs25487 Arg/Arg (49/40) Arg/Gln (45/39) Gln/Gln (10/8) 0.9752
TP53 Arg72Pro rs1042522 Arg/Arg (52/47) Arg/Pro (40/35) Pro/Pro (12/5) 0.3733
CYP2E1 96bp insertion −/− (100/74) −/ins (4/13) ― 0.0097
CYP2E1 − 1053 C/T rs2031920 CC (102/68) CT (2/18) ― <0.0001
CYP2E1 7632 T/A rs6413432 TT (91/67) TA (12/20) AA (1/0) 0.0753
CYP2E1 9896 C/G rs2070676 CC (82/78) CG (20/9) GG (2/0) 0.0908
*The first value in parentheses means the number of patients with corresponding genotype in Russian group, the second 
one – in Yakut group.
**The genotype was defined as positive if at least one copy of gene was present.
***The corresponding genotype was not occurred in populations.
NA – not available (not determined with the genotyping method used).
Table 1. Genotype frequencies in Russian and Yakut patients.
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The median progression-free survival (PFS) in the Russian group was 12 months, and the 
median overall survival (OS) was 55 months. In the Yakut group, both intervals were shorter 
—8 and 29 months, respectively. However, being adjusted for disease stage, the values became 
similar to those for the Russian group.
More contrast results were obtained in analysis of occurrence of adverse events. To assess 
the association between genotype and the toxicity of the treatment used, patients were classi-
fied as having good or poor tolerance to treatment (grades 3–4 of neutropenia, grades 2–4 of 
anemia, grades 2–4 of neuropathy, grades 3–4 of emesis, all grade of thrombocytopenia, neph-
rotoxicity, and ototoxicity were considered as clinically significant toxicities). Comparison of 
the frequencies of side effects registered in Russian and Yakut patients confirmed higher tox-
icity of platinum-based regimens for patients of Asian origin than for Europeans. Particularly, 
Yakut patients suffered more frequently than Russians from nephrotoxicity and severe eme-
sis (P = 0.027 and P = 0.061, respectively), which both were known to be the most common 
adverse events observed in regimens using cisplatin [28].
Genetic testing of the patients from our groups was performed in two stages. At first, we 
explored the associations between outcomes of a cisplatin-cyclophosphamide regimen in 
Russian and Yakut ovarian cancer patients and some most common polymorphisms in several 
genes [21, 22], among the tested genes, were glutathione S-transferase (GST) genes (GSTA1, 
GSTM1, GSTM3, GSTP1 and GSTT1), DNA repair genes (ERCC1, ERCC2 and XRCC1) as well 
as TP53 and CYP2E1 genes (Table 1). GST and DNA repair genes have been described as 
important for cisplatin metabolism and activity [29, 30]. GSTs can directly limit the amount 
of reactive cisplatin species available for interaction with DNA, by catalyzing their binding 
to tripeptide glutathione. The resulting cisplatin-glutathione conjugates can be further eas-
ily excreted from the cell by the GS-X pump transporters [31]. DNA repair proteins remove 
platinum-DNA adducts, the persistence of which underpins the antitumor potential of plati-
num drugs. In contrast to GST and the DNA repair proteins, TP53 protein does not seem to 
directly affect cisplatin metabolism or transformation. At the same time, it has a crucial role 
in mediating cellular responses to DNA damage, initiating programmed cell death when the 
effective DNA repair is impossible [29, 30, 32]. There is also no evidence that cisplatin is 
metabolized by CYP2E1. However, CYP2E1 is a significant potential source of catalytic iron 
and can serve as a site for generating reactive oxygen species in the presence of cisplatin [33]. 
It has been proposed that this mechanism underlies cisplatin-induced nephrotoxicity and 
hepatotoxicity [34, 35].
One of the most significant associations found in the first part of the study was the correlation 
between the survival time intervals and GSTP1 Ile105Val polymorphism registered in Russian 
subjects (P = 0.004 and P = 0.016 for PFS and OS, respectively). Russian ovarian cancer patients 
with a homozygous Ile/Ile genotype had longer PFS and OS than those ones who carried Ile/
Val and Val/Val genotypes. However, the association was not observed in Yakut patients. PFS 
and OS of Yakut women with Ile/Ile genotype did not differ from the corresponding time 
intervals of patients with 1 or 2 Val alleles. In the Yakut group, PFS correlated with CYP2E1 
7632 T/A polymorphism (P = 0.015), being longer in patients with a homozygous TT genotype 
than in patients with the heterozygous TA genotype.
Analysis of genotype distribution in the population groups for toxicities revealed that occur-
rence of nephrotoxicity and severe emesis in Yakut patients correlated with GSTT1 and 
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CYP2E1 genotypes, respectively. Patients with a homozygous GSTT1 gene deletion (GSTT1 
null) suffered more frequently from nephrotoxicity than carriers of functional GSTT1 vari-
ants (OR = 3.31, 95% CI 1.15–9.54, P = 0.028). Patients who had a 96 bp insertion in the pro-
moter region of the CYP2E1 were more prone to severe emesis (OR = 4.69, 95% CI 1.31–16.77, 
P = 0.027). Grade 3 or 4 emesis was also associated with another CYP2E1 polymorphism—a 
single nucleotide substitution (9896 C/G) in intron 7. Patients with a heterozygous CG gen-
otype had a higher risk of severe emesis than patients with the homozygous CC genotype 
(OR = 16.96, 95% CI 2.01–143.16, P = 0.002). In contrast, in Russian patients, CYP2E1 polymor-
phisms were not associated with any clinical outcomes and distribution of GSTT1 genotypes 
correlated with severity of emesis. The risk of severe emesis was higher in Russian patients 
with the GSTT1-null genotype than in patients with a functional GSTT1 variant (OR = 4.06, 
95% CI 1.40–11.78; P = 0.014). As for the nephrotoxicity in Russian subjects, it was associated 
with ERCC1 19007 T/C or 8092 C/A polymorphisms, and cases of renal dysfunction were more 
prevalent among patients with the heterozygous genotypes of each locus. Other found gen-
otype-clinical end point associations were also discordant in Russians and Yakuts (Table 2).
When genotype distributions in both groups were compared significant differences in popu-
lation genotype frequencies were noted for 10 of 19 polymorphisms studied but only 5 of 
them were associated with clinical outcomes (Tables 1 and 2).
Evaluation of the direction/strength of the associations showed that they were not correlated 
with the differences in population frequencies of corresponding genotypes. For example, the 
absence of correlation between the GSTP1 Ile105Val polymorphism and survival in Yakut 
patients was not simply due to the higher prevalence of Ile/Ile genotype among them because 
carriers of Ile/Ile genotype did not differ in PFS or OS from those who had genotypes with 1 or 
2 Val alleles. Similar results were obtained for the GSTA1-69 C/T polymorphism. Its CT and TT 
genotypes were associated with a risk of anemia in Yakuts; yet the greater frequencies of the CT 
and TT genotypes in Russians did not result in a higher risk of anemia. Similarly, risk genotypes 
of ERCC1 19007 T/C and ERCC2 Asp312Asn polymorphisms (i.e., heterozygous genotypes in 
Russians) were not rare among Yakut patients but they did not demonstrate correlations with 
the corresponding side effects (Tables 1 and 2). It seems that only in the case of CYP2E1 96 bp 
insertion polymorphism an effect of allele frequency differences could be proposed  but due to 
small number of individuals with the insertion containing genotypes in Russians  the suggestion 
requires verification in a larger sample.
Taken in the context of other data, the obtained results generally supported the role of eth-
nicity as an additional reason for differences in the outcomes of clinical trials in which the 
same treatment is used. At the same time, the results of genetic testing suggested that a single 
genotypic difference was unlikely to account for the observed ethnic variation in toxicity and 
survival. Moreover, they also suggested that assessing traditionally tested common polymor-
phisms in GST and DNA repair genes is not enough for relevant description of lesser toler-
ability of Asians (North/East Asians) to the effects of platinum-containing chemotherapies 
and further studies involving more polymorphic markers are required.
In the second part of our study, we systematically investigated the associations between 
patients’ outcomes and SNPs in more than 100 genes using the microarray “DNA repair sin-
gle nucleotide polymorphism detection test” (version 2) [36, 37]. Like similar genotyping pan-
els, the list of genes tested comprised candidate genes involved in key pathways of cellular 
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Gene name #rs ID Clinical outcomes**
PFS OS Anemia Neutropenia Thrombocitopenia Nephrotoxicity Ototoxicity Emesis
R Y R Y R Y R Y R Y R Y R Y R Y
GSTA1 rs3957357 +
GSTM1 gene deletion + +
GSTM3 rs1799735 + +
GSTM3 rs7483
GSTP1 rs1695 + +
GSTP1 rs1138272













*The registered associations are indicated by “+” in the corresponding cells.
**Tumor response and ototoxicity were not included in the table as there were no associations between them and polymorphisms tested.
Table 2. The associations between polymorphisms and clinical outcomes observed in Russian (R) and Yakut (Y) patient groups (the first stage of the study)*.
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response to different drugs [38, 39], including many genes that are related to the cisplatin 
pathway (platinum pathway) [40]. A total of 213 SNPs from 228 genotyped SNPs were new 
(i.e., they did not include SNPs from the first stage) and 27 SNPs were associated with one or 
more of the assessed clinical end points (Table 3).
Increasing number of polymorphisms yielded an association with tumor response. To assess 
the association, patients who achieved a complete remission were compared with those with-
out it (i.e., patients with partial response, stable and progressive disease). In the Russian group, 
a significant difference in complete response was observed according to polymorphism in 
the ADH1C gene (A/G, rs698) (P = 0.0002). The proportion of patients who achieved a com-
plete response was higher among carriers of homozygous genotypes AA and GG compared 
with patients with a heterozygous variant AG. In Yakut patients, the occurrence of complete 
response was correlated with an allelic status of SNP in CDKN1B gene (T/C, rs34330), particu-
larly with an allele C. There were no cases of complete remission among patients who carried 
a homozygous genotype TT at rs34330. The SNP was also associated with PFS in Yakut sub-
jects (P = 0.0051); patients with the genotype TT had shorter PFS than patients with CC and CT 
genotypes. The protein encoded by CDKN1B gene participates in regulation of the cell cycle 
by binding and inhibiting activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus 
blocking the transition of the cell into the S-phase. C > T substitution at rs34330 locus results in 
decreasing the levels of mRNA and CDKN1B protein [41]. Reduced level of CDKN1B expres-
sion has been associated with a poor outcome in various cancers [42, 43]. In contrast, the 
ADH1C SNP (rs698) has been associated with a risk of alcoholism and ethanol-related cancers 
[44], but our study was the first to demonstrate an association with a chemotherapy outcome 
(i.e., tumor response) but the mechanism is not obvious.
Genotypes of seven SNPs were associated with differences in PFS in the Russian group (Table 3). 
The most significant SNPs were rs1142345 (A/G) in TPMT (P = 3 × 10−8) and rs4986998 (C/T) 
and rs1800566 (C/T) in NQO1 genes (P = 2 × 10−6 and P = 9 × 10−11, respectively). The longer PFS 
was seen in patients with the most frequent genotypes AA and CC. SNPs in NQO1 demon-
strated similar correlations with OS.
Thiopurine S-methyltransferase (TPMT) is a cytosolic methylating enzyme with unknown 
physiological role [45]. However, this enzyme is known to be able to catalyze the S-methylation 
of some aromatic and heterocyclic compounds, particularly thio-compounds (e.g., 6-mercap-
topurine and 6-thioguanine). Discussing the associations revealed between SNPs in TPMT 
and cisplatin ototoxicity, Ross et al. [46] have hypothesized that TPMT can affect cisplatin-
induced hearing impairment through inactivation of cisplatin-purine compounds that form 
cytotoxic DNA cross-links, and cause cell death. As might be expected from that data, those 
patients in our study who had the loss-of-function genotype AG at rs1142345 should demon-
strate a better outcome as a result of decreased inactivation of cisplatin-purine compounds, 
but such a correlation was not observed. Moreover, patients with an AG genotype had even 
shorter PFS than those who carried the functionally normal AA genotype.
The tested SNPs in NQO1 gene are characteristic polymorphic variants affecting functional 
ability of the corresponding protein — a cytosolic flavoenzyme NAD(P)H: quinone oxidore-
ductase 1 (NQO1). NQO1 polymorphic status has been associated with anticancer chemotherapy 
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Gene name #rs ID Clinical outcomes
Response PFS OS Anemia Neutropenia Thrombocitopenia Nephrotoxicity Ototoxicity Emesis
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Gene name #rs ID Clinical outcomes
Response PFS OS Anemia Neutropenia Thrombocitopenia Nephrotoxicity Ototoxicity Emesis
R Y R Y R Y R Y R Y R Y R Y R Y R Y
NBN rs1063045 +
NQO1 rs1800566 + +
NQO1 rs4986998 + +
RAD52 rs11226 +
TPMT rs1142345 +
*The designations are the same as in Table 2.
Table 3. The associations between polymorphisms and clinical outcomes observed in Russian (R) and Yakut (Y) patient groups (the second stage of the study)*.
Ethnic D





outcome (i.e., individuals with CT and TT genotypes at rs1800566 showed reduced survival 
compared to CC homozygotes) [47, 48]. The same correlations were observed in our study. 
Taking into account the key role of NQO1 in preventing the formation of reactive semiqui-
none radicals and generating reactive oxygen species (ROS) via redox cycling, one can pro-
pose that the worse survival of carriers of CT and TT genotypes is at least the consequence of 
a chronically elevated level of ROS, which results in enhanced ROS-mediated DNA damage, 
increased genetic instability, and further cancer progression [47].
In addition to CDKN1B, SNPs in CYP1A1 (T/C, rs4646903) and CYP1A2 (C/T, rs2470890) were 
found to also be associated with survival, particularly with OS, in Yakut patients (P = 0.007 
and P = 0.0072, respectively). In each case the longer OS occurred in patients with homo-
zygous genotypes TT. In contrast to TPMT and NQO1, the role of CYP1A1 and CYP1A2 in 
cisplatin metabolism or toxicity is difficult to discern. At the same time, it cannot be excluded 
that the observed associations are related to metabolic pathways of drugs used in the second 
and subsequent lines of the chemotherapy (taxanes and anthracyclines).
Totally, 16 SNPs were associated with the side effects of chemotherapy. Thirteen such SNPs 
were revealed in the Russian group and three SNPs in Yakuts (Table 3). A total of 6 of 13 SNPs 
were associated with an incidence of severe neutropenia in Russian patients. A strong associa-
tion was estimated for SNP rs1052536 in LIG3. Carriers of its homozygous genotype CC had 
more than 20-fold higher risk of grade 3 or 4 neutropenia than patients with other genotypes 
(OR = 23.211, 95% CI =2.976–181.02, P = 2 × 10−6). However, the most significant was SNP 
rs3219484 in MUTYH. The SNP was represented by only two genotypes, and patients who 
carried a heterozygous genotype AG had very low (actually unobserved) risk of developing 
severe neutropenia (OR = 0.013, 95% CI 0.000–0.220, P = 4 × 10−8). MUTYH encodes a DNA gly-
cosylase involved in repair of oxidatively damaged DNA, in particular by excising adenines 
misincorporated opposite 7,8-dihydro-8-oxoguanines. Such mispairs are promutagenic, and 
if left unrepaired before the next round of replication, they can give rise to CG → AT transver-
sion mutations [49]. The observed association may reflect the substantial contribution of oxi-
dative stress (i.e., ROS) into cisplatin-induced cytotoxicity. On the other hand, an associative 
grouping of MUTYH SNPs together with SNPs from other DNA repair genes, particularly 
RAD52 and ERCC5, may also indicate a role of MUTYH in the repair of cisplatin-produced 
DNA lesions (e.g., participation in detection of the lesions) [50].
Another side effect for which multiple associations were found in the Russian group was ane-
mia. SNPs in NAT2, GSTA4, CCNH, and EPHX1 genes were associated with the toxicity (Table 3). 
The most significant was SNP rs1801280 in NAT2. Cases of anemia occurred more frequently 
among patients with the heterozygous CT genotypes (78.4%) compared with the homozygous 
variants (OR = 5.945, 95% CI 2.351–15.031, P = 0.00009). This association is of particular interest 
because there is no information about a role of NAT2 in the metabolism or toxicity of cisplatin 
or cyclophosphamide (the second drug in our chemotherapy regimen) [51]. One can propose 
that the association found is due to linkage between the SNP with a functional SNP(s) in other 
gene(s). Unlike NAT2, three other genes (i.e., GSTA4, CCNH, and EPHX1) are more relevant to 
the effects of intracellular processing of cisplatin. The cyclin encoded by CCNH is a part of a 
TFIIH complex that is an essential component of a nucleotide excision repair pathway, widely 
accepted as a main player in removing platinum-DNA adducts from DNA molecules [52]. 
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GSTA4 plays an important role for the detoxification of 4-hydroxynonenal [53], a toxic prod-
uct of lipid peroxidation, increasing immensely under oxidative stress conditions (e.g., over-
production of ROS), including cisplatin treatment [54, 55]. The role of epoxide hydrolases 
(EPXHs) in cisplatin-induced toxicity appears to be also related to the effects of oxidative stress. 
However, in contrast to GSTA4, EPXHs role is inhibitory and results from the abilities of epox-
ide hydrolases to metabolize epoxyeicosatrienoic acids (EETs) possessing multiple functions, 
particularly anti-inflammatory effects. The data about relationships between EET hydrolysis 
and cisplatin toxicity have been mainly obtained from the studies of cisplatin nephrotoxicity 
[56, 57]. It has been shown that the anti-inflammatory effect of EETs substantially depends on 
EPHX2, a cytosolic partner of EPHX1. EPHX1 also accepts EETs, although generally to a much 
lesser extent than EPHX2 [58]. Therefore, a role for EPHX1 in cisplatin toxicity should not be 
excluded, particularly because of its high expression in kidneys. The association between the 
SNP rs1051740 in EPHX1 and nephrotoxicity of the regimen used supports this suggestion.
Three SNPs in APEX1 (rs1048945), MSH3 (rs26279), and MSH6 (rs1042821) were associated with 
ototoxicity, thrombocytopenia, and emesis in Russian patients (Table 3). APEX1 gene encodes 
apurinic/apyrimidinic endodeoxyribonuclease 1 playing an essential role in the DNA base exci-
sion repair pathway, where it removes apurinic/apyrimidinic sites produced during the repair 
of bases modified by ROS, alkylating agents, or ionizing radiation [59]. High APEX1 expression 
has been associated with a poor outcome for chemoradiotherapy, poor complete response rate, 
shorter local relapse-free interval, poorer survival, and high angiogenesis [59]. At the same time, 
a role for APEX1 in protection against toxicity, particularly neurotoxicity, induced by ionizing 
radiation, and cisplatin treatment, has also been demonstrated [60–62]. ROS and oxidative DNA 
damage induced by them were shown to be important components of the deleterious effects of 
cisplatin on neuronal cells. Taking into account the proposed role of ROS in the mechanism of 
cisplatin-induced hearing loss [63], a contribution of APEX1 can also be hypothesized.
The protein products of MSH3 and MSH6 are essential components of the DNA mismatch 
repair system (MMR). The presence of MMR is thought to be important in mediating cisplatin 
and carboplatin cytotoxicity, whereas its deficiency, by contrast, may contribute to desensiti-
zation of cancer cells to the drugs [64, 65]. In our study, SNPs in MSH3 and MSH6 were not 
associated with tumor response or survival. Nevertheless, patients with minor alleles of the 
SNPs rs26279 and rs1042821 were at higher risk of thrombocytopenia and emesis, respectively.
Only one gene from the list above was also present among the genes whose polymorphisms 
were associated with the adverse reactions in Yakut patients, namely, EPXH1 gene. However, 
it was associated with a different side effect (i.e., ototoxicity). Furthermore, the corresponding 
polymorphisms were also different (A/G, rs2234922 and C/G, rs2260863) (Table 3). Higher 
risk of ototoxicity was observed in patients with the most frequent genotypes AA and CC 
(OR = 26.26, 95% CI 1.502–458.98, P = 0.0005). Although the role of EPXHs in cisplatin toxicity 
has been mainly associated with their effects on cisplatin-induced kidney injury, the observed 
link between the EPHX1 polymorphism and cisplatin ototoxicity can be due to similarity of 
mechanisms underlying cisplatin-induced hearing impairment and renal dysfunction [66].
The second gene whose allelic variants were associated with a side effect of chemotherapy in 
Yakut patients (i.e., severe emesis) was NBN (G/A, rs1063045). The risk factor for the development 
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of severe emesis in patients was their heterozygous status at the rs1063045 locus. The protein 
encoded by NBN gene is an important component of the system repairing DNA double-strand 
breaks that can be induced by different environmental and endogenous agents, including cis-
platin. The existing data suggest connections between polymorphic variants of the NBN gene 
and the results of cisplatin-based chemotherapy [67].
Intergroup comparison of genotypes generated with the microarrays revealed substantial dif-
ferences in population frequencies of alleles and genotypes for many polymorphic markers. 
More than half of all markers differed significantly in the occurrence of their allelic variants 
in Russian and Yakut patients.
The proportion of significant genotype frequency differences resembled the results obtained 
in the first part of the study where a smaller number of polymorphic markers was involved 
(Table 2). Furthermore, the results of the comparisons of population-related associative 
spectra were also the same: there were no identical correlations for any of significant poly-
morphisms. All associations between the polymorphic markers and clinical outcomes were 
specific for each of the ethnic group studied.
These findings are generally compatible with the results of the HapMap project studying of 
the toxicity of platinum compounds (i.e., cisplatin and carboplatin) to lymphoblastoid cell 
lines from three groups of racially different individuals [19]. One can propose that the fail-
ure to detect common associations/commonly associated polymorphisms in our two groups 
was due to distinctive ethnic-related characteristics in the molecular mechanisms determin-
ing the sensitivity of patients to platinum drugs. Hence the difference in platinum drug 
sensitivity might not exclusively depend on the difference in variant frequencies of given 
polymorphisms. Another, but not exclusive, explanation of the findings could be a limita-
tion of the number of polymorphisms tested and a possible omission of other potentially 
important markers. The latest may be mainly due to the misunderstanding of molecular 
phenotype(s) of the particular drug(s) [68]. The more relevant is the molecular phenotype, 
the higher is the potential to optimize the use of a particular drug. For some drugs, such 
as fluorouracil, irinotecan, and mercaptopurine, some relevant variants (i.e., DPYD*2A, 
DPYD 2846T/A, and TYMS 2R/3R; UGT1A1*28 and UGT1A1*6; TPMT *2, TPMT *3A, and 
TPMT*3C) have been established but for other ones, including platinum-containing agents, 
they are less apparent [68, 69].
The importance of DNA repair, particularly nucleotide excision repair, for platinum cyto-
toxicity is widely accepted [64]. However, the overall contribution of even the most com-
mon genetic variants to predictions of response to platinum-based therapy is not yet well 
established [70, 71]. In principle, the situation with other “canonical” pathways affecting 
mainly cisplatin pharmacokinetics could be described the same way [72]. Therefore, the role 
of additional mechanisms that are not directly related to cisplatin cellular processing has also 
been proposed [73]. The results of our study overrepresented with the associations with poly-
morphisms in genes for different metabolic enzymes (TPMT, NQO1, EPXH1, etc.) supports 
the suggestion (the associations would remain significant even if they were adjusted with 
the Bonferroni method). The abundance of associations with genes involved in processing of 
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ROS or ROS-mediated lesions is of particular interest. First, it can point to the higher poten-
tial of ROS in total cisplatin-related cytotoxicity [66, 73]. Second, it has been proposed that 
populations from different geographic regions possess a difference in efficiency of coupling 
mitochondrial oxidation with phosphorylation, with more heat production and lower ROS 
generation in North/Northeastern Asians [74, 75]. Consequently, we can expect in Asians 
lower ability to utilize extra ROS and higher sensitivity to effects of platinum-based drugs. 
However, because of the relatively small sample sizes and limited number of markers tested, 
further studies are required to confirm this hypothesis.
In summary, comprehensive exploration of genotypes of polymorphisms in more than 100 
genes in ovarian cancer patients from Russian and Yakut ethnic groups, receiving cisplatin-
based chemotherapy, revealed pronounced differences in associative spectra between them. 
Taken in the context of absence of correlations between the associations and polymorphic 
genotype frequencies, the differences suggest a potential for distinct ethnic-related molecu-
lar mechanisms determining the sensitivity of patients to platinum drug effects. The mecha-
nisms are thought to be associated with activity of different metabolic enzymes, including 
those involved in processing the reactive oxygen species. These genetic findings and differ-
ential responses to platinum-based chemotherapy between ethnic groups suggest that future 
genetic testing may be invaluable not only in predicting chemotherapy response but also in 
deciding the most appropriate chemotherapy regimen. It may be possible to identify in detail 
the susceptibility differences to chemotherapy sensitivity at the molecular level and harness 
this for therapeutic gains.
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